Ein Gedi Cosmetics & Pharma ltd – Trademark Portfolio

Entity Type: 99

Ein Gedi Cosmetics & Pharma ltd holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 7 filings in this category. Currently, 6 trademarks are registered. Notable registered marks include KING DAVID, KING SOLOMON, LION OF JUDAH, SECOND COMING, and ESSENCE OF JERUSALEM. The owner is based in Ashdod.

62 Hahadarim St. Office #206

Ashdod 7761301 , IL

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Ein Gedi Cosmetics & Pharma ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

3
Cosmetics & Cleaning (7 filings)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does Ein Gedi Cosmetics & Pharma ltd have?

Ein Gedi Cosmetics & Pharma ltd has 7 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 abandoned.

What trademark classes does Ein Gedi Cosmetics & Pharma ltd file in?

Ein Gedi Cosmetics & Pharma ltd files trademarks across 1 Nice Classification class. The most active classes are Class 3 (Cosmetics & Cleaning). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.

What are Ein Gedi Cosmetics & Pharma ltd's most well-known trademarks?

Ein Gedi Cosmetics & Pharma ltd's registered trademark portfolio includes well-known marks such as KING DAVID, KING SOLOMON, LION OF JUDAH, SECOND COMING, and ESSENCE OF JERUSALEM. These are among 6 currently registered trademarks in the portfolio.

What is Ein Gedi Cosmetics & Pharma ltd's trademark registration success rate?

Ein Gedi Cosmetics & Pharma ltd has a 86% trademark registration rate, with 6 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.